KCC009
Code | Size | Price |
---|
TAR-T27717-50mg | 50mg | £870.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T27717-100mg | 100mg | £1,267.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
KCC009 is a potent and selective Transglutaminase 2 Inhibitor.
CAS:
744198-19-4
Formula:
C21H22BrN3O5
Molecular Weight:
476.327
Purity:
0.98
SMILES:
Oc1ccc(C[C@H](NC(=O)OCc2ccccc2)C(=O)NCC2CC(Br)=NO2)cc1
References
1. Huaying S, Dong Y, Chihong Z, Xiaoqian Q, Danying W, Jianguo F. Transglutaminase 2 Inhibitor KCC009 Induces p53-Independent Radiosensitization in Lung Adenocarcinoma Cells. Med Sci Monit. 2016 Dec 21;22:5041-5048. PubMed PMID: 28002389; PubMed Central PMCID: PMC5198751.
2. Yuan L, Siegel M, Choi K, Khosla C, Miller CR, Jackson EN, Piwnica-Worms D, Rich KM. Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy. Oncogene. 2007 Apr 19;26(18):2563-73. PubMed PMID: 17099729.
3. Strnad P, Siegel M, Toivola DM, Choi K, Kosek JC, Khosla C, Omary MB. Pharmacologic transglutaminase inhibition attenuates drug-primed liver hypertrophy but not Mallory body formation. FEBS Lett. 2006 Apr 17;580(9):2351--2357. PubMed PMID: 16616523.
4. Konoplyannikov M, Nurminskaya M. New therapeutic approaches to arterial calcification via inhibition of transglutaminase and ?-catenin signaling. Curr Pharm Des. 2014;20(37):5811-20. Review. PubMed PMID: 24533936.